SWOG clinical trial number
CTSU/EA3161
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Open
Phase
Abbreviated Title
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Status Notes
SWOG Activated: 1/21/2020
Activated
06/20/2019
Research committees
Early Therapeutics & Rare Cancers
Treatment
Cisplatin
Nivolumab
Other Clinical Trials
SWOG Clinical Trial Number
S2505
Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
07/06/2026
Open
SWOG Clinical Trial Number
SN2426
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Sarcoma
Activated
01/28/2026
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open